Jim DeTore
About Jim DeTore
Jim DeTore, age 61, was appointed interim principal financial and accounting officer of CG Oncology effective November 17, 2025, via a consulting engagement with Monomoy Advisors LLC; he is responsible for the Company’s financial and accounting functions and is eligible for the Company’s standard indemnification agreement . His prior roles include CFO at Neurogastrx (June 2021–June 2025), CFO at Proteostasis Therapeutics (Aug 2016–Feb 2017), CFO at bluebird bio (Nov 2014–Feb 2016), and independent CFO consulting to early/mid-stage biopharma companies (Mar 2017–May 2021); he holds BS and MBA degrees from Northeastern University . No performance outcomes (TSR, revenue growth, EBITDA growth) tied to his tenure at CG Oncology have been disclosed .
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| Neurogastrx, Inc. | Chief Financial Officer | Jun 2021–Jun 2025 | Senior finance leadership as CFO |
| Independent consulting (various biopharma) | CFO services (consultant) | Mar 2017–May 2021 | Provided CFO services to early/mid-stage biotech/pharma companies |
| Proteostasis Therapeutics | Chief Financial Officer | Aug 2016–Feb 2017 | Senior finance leadership as CFO |
| bluebird bio, Inc. | Chief Financial Officer | Nov 2014–Feb 2016 | Senior finance leadership as CFO |
External Roles
No current public company board roles or committee positions for DeTore are disclosed in CG Oncology filings .
Fixed Compensation
| Component | Nov 2025 | Dec 2025 onward |
|---|---|---|
| Monthly consulting fee to Monomoy Advisors LLC | $32,000 (prorated partial month) | $64,000 per month |
| Initial term | Minimum 3 months | Option to extend additional 3 months |
Performance Compensation
| Metric | Weighting | Target | Actual | Payout | Vesting |
|---|---|---|---|---|---|
| None disclosed for consulting engagement | — | — | — | — | — |
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Beneficial ownership | Not disclosed; DeTore was not among officers/directors listed as of April 8, 2025 in the beneficial ownership table |
| Options/RSUs at CG Oncology | None disclosed with appointment; 8-K specifies consulting compensation only |
| Shares pledged as collateral | Company policy prohibits pledging without prior Board approval; hedging and derivatives transactions are prohibited |
| Insider trading/hedging policy | Prohibits hedging, trading in publicly-traded options (other than company grants), and holding stock in margin accounts |
| Clawback | Company maintains a Dodd-Frank-compliant clawback policy; SOX 304 reimbursement may apply to CEO/CFO after misconduct-related restatement |
Employment Terms
| Term | Detail |
|---|---|
| Role/title | Interim principal financial and accounting officer |
| Agreement structure | Consulting Agreement with Monomoy Advisors LLC |
| Compensation | $32,000 for Nov 2025 (prorated), then $64,000 per month thereafter |
| Term | Minimum 3 months, option to extend 3 months |
| Termination | 60-day notice by either party; or for material breach not cured in 30 days |
| Indemnification | Eligible to enter Company’s standard form of indemnification agreement |
| Related parties | No Item 404(a) related-party transactions; no family relationships with directors/executives |
| Non-compete/Non-solicit | Not disclosed |
Investment Implications
- The CFO seat experienced multiple transitions in 2025 (Roche resigned Aug 5; Lapetina served as interim; DeTore appointed Nov 17 via a short-term consulting engagement), signaling near-term finance leadership transition risk that investors should monitor .
- DeTore’s arrangement is cash-based with no disclosed equity awards, limiting long-term alignment and reducing immediate insider selling pressure from this executive; this is offset by corporate hedging/pledging prohibitions that support alignment for all insiders .
- The presence of a Dodd-Frank-compliant clawback policy and SOX 304 reimbursement framework provides governance safeguards around financial reporting responsibility for the principal financial and accounting officer role .
- With consulting terms set at $64,000 per month and a minimum three-month horizon, cost visibility is high but retention is inherently short-term; investors should watch for conversion to a permanent CFO, equity grant disclosures, and any updates to compensation structure tied to performance objectives .